請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/94954完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 林芯伃 | zh_TW |
| dc.contributor.advisor | SHIN-YU Lin | en |
| dc.contributor.author | 王羿婷 | zh_TW |
| dc.contributor.author | YI-TING Wang | en |
| dc.date.accessioned | 2024-08-21T16:52:36Z | - |
| dc.date.available | 2024-08-22 | - |
| dc.date.copyright | 2024-08-21 | - |
| dc.date.issued | 2024 | - |
| dc.date.submitted | 2024-07-30 | - |
| dc.identifier.citation | 1.施景中、謝豐舟（1999）。婦產科：立體超音波的原理與臨床應用。台灣醫學，3(5)，631-635。
2.Hsieh, F. J., Ko, T. M., Tseng, L. H., Chang, L. S., Pan, M. F., Chuang, S. M., Lee, T. Y., & Chen, H. Y. (1992). Prenatal cytogenetic diagnosis in amniocentesis. Journal of the Formosan Medical Association = Taiwan yi zhi, 91(3), 276–282. 3.Avram, C. M., Caughey, A. B., Norton, M. E., & Sparks, T. N. (2022). Cost-Effectiveness of Exome Sequencing versus Targeted Gene Panels for Prenatal Diagnosis of Fetal Effusions and Non-Immune Hydrops Fetalis. American journal of obstetrics & gynecology MFM, 4(6), 100724. 4.Chen, H. Y., Lin, S. Y., Shih, J. C., Kang, J., Tai, Y. Y., Shaw, S. W., Chen, K. C., Mai, K., & Lee, C. N. (2024). Changing the standardised obstetric care by expanded carrier screening and counselling: a multicentre prospective cohort study. Journal of medical genetics, 61(2), 176–181. 5.Reis, F. C., Alexandrino, F., Steiner, C. E., Norato, D. Y., Cavalcanti, D. P., & Sartorato, E. L. (2005). Molecular findings in Brazilian patients with osteogenesis imperfecta. Journal of applied genetics, 46(1), 105–108. 6.Lin, H. Y., Chuang, C. K., Su, Y. N., Chen, M. R., Chiu, H. C., Niu, D. M., & Lin, S. P. (2015). Genotype and phenotype analysis of Taiwanese patients with osteogenesis imperfecta. Orphanet journal of rare diseases, 10, 152. 7.Zhytnik, L., Maasalu, K., Reimand, T., Duy, B. H., Kõks, S., & Märtson, A. (2020). Inter- and Intrafamilial Phenotypic Variability in Individuals with Collagen-Related Osteogenesis Imperfecta. Clinical and translational science, 13(5), 960–971. 8.Niu, D. M., Hsiao, K. J., Wang, N. H., Chin, L. S., & Chen, C. H. (1996). Chinese achondroplasia is also defined by recurrent G380R mutations of the fibroblast growth factor receptor-3 gene. Human genetics, 98(1), 65–67. 9.Hung, C. C., Lee, C. N., Chang, C. H., Jong, Y. J., Chen, C. P., Hsieh, W. S., Su, Y. N., & Lin, W. L. (2008). Genotyping of the G1138A mutation of the FGFR3 gene in patients with achondroplasia using high-resolution melting analysis. Clinical biochemistry, 41(3), 162–166. 10.Bellus, G. A., Hefferon, T. W., Ortiz de Luna, R. I., Hecht, J. T., Horton, W. A., Machado, M., Kaitila, I., McIntosh, I., & Francomano, C. A. (1995). Achondroplasia is defined by recurrent G380R mutations of FGFR3. American journal of human genetics, 56(2), 368–373. 11.Ornitz, D. M., & Legeai-Mallet, L. (2017). Achondroplasia: Development, pathogenesis, and therapy. Developmental dynamics : an official publication of the American Association of Anatomists, 246(4), 291–309. 12.Northrup H, Koenig MK, Pearson DA, et al. Tuberous Sclerosis Complex. 1999 Jul 13 [Updated 2021 Dec 9]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1220/ 13.Jones, A. C., Shyamsundar, M. M., Thomas, M. W., Maynard, J., Idziaszczyk, S., Tomkins, S., Sampson, J. R., & Cheadle, J. P. (1999). Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. American journal of human genetics, 64(5), 1305–1315. 14.Hong, C. H., Darling, T. N., & Lee, C. H. (2009). Prevalence of tuberous sclerosis complex in Taiwan: a national population-based study. Neuroepidemiology, 33(4), 335–341. 15.Smith RJH. Branchiootorenal Spectrum Disorder. 1999 Mar 19 [Updated 2018 Sep 6]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1380/ 16.Beyzaei, Z., Mehrzadeh, A., Hashemi, N., & Geramizadeh, B. (2023). The mutation spectrum and ethnic distribution of Wilson disease, a review. Molecular genetics and metabolism reports, 38, 101034. 17.Shen, Y., Tang, X., Chen, Q., Xu, H., Liu, H., Liu, J., Yang, H., Li, H., & Zhao, S. (2022). Genetic spectrum of Chinese children with cystic fibrosis: comprehensive data analysis from the main referral centre in China. Journal of medical genetics, 60(3), 310–315. Advance online publication. 18.Chen, H. J., Lin, S. P., Lee, H. C., Chen, C. P., Chiu, N. C., Hung, H. Y., Chern, S. R., & Chuang, C. K. (2005). Cystic fibrosis with homozygous R553X mutation in a Taiwanese child. Journal of human genetics, 50(12), 674–678. 19.Laugel V. Cockayne Syndrome. 2000 Dec 28 [Updated 2019 Aug 29]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from:https://www.ncbi.nlm.nih.gov/books/NBK1342/ 20.Yu, S., Chen, L., Ye, L., Fei, L., Tang, W., Tian, Y., Geng, Q., Yi, X., & Xie, J. (2014). Identification of two missense mutations of ERCC6 in three Chinese sisters with Cockayne syndrome by whole exome sequencing. PloS one, 9(12), e113914. 21.He, C., Sun, M., Wang, G., Yang, Y., Yao, L., & Wu, Y. (2017). Two novel mutations in ERCC6 cause Cockayne syndrome B in a Chinese family. Molecular medicine reports, 15(6), 3957–3962. 22.Iwasa, Y. I., Nishio, S. Y., Yoshimura, H., Sugaya, A., Kataoka, Y., Maeda, Y., Kanda, Y., Nagai, K., Naito, Y., Yamazaki, H., Ikezono, T., Matsuda, H., Nakai, M., Tona, R., Sakurai, Y., Motegi, R., Takeda, H., Kobayashi, M., Kihara, C., Ishino, T., … Usami, S. I. (2022). Detailed clinical features and genotype-phenotype correlation in an OTOF-related hearing loss cohort in Japan. Human genetics, 141(3-4), 865–875. 23.Chiu, Y. H., Wu, C. C., Lu, Y. C., Chen, P. J., Lee, W. Y., Liu, A. Y., & Hsu, C. J. (2010). Mutations in the OTOF gene in Taiwanese patients with auditory neuropathy. Audiology & neuro-otology, 15(6), 364–374. 24.Zhu, Y. M., Li, Q., Gao, X., Li, Y. F., Liu, Y. L., Dai, P., & Li, X. P. (2021). Familial Temperature-Sensitive Auditory Neuropathy: Distinctive Clinical Courses Caused by Variants of the OTOF Gene. Frontiers in cell and developmental biology, 9, 732930. 25.Burgmaier K, Gimpel C, Schaefer F, et al. Autosomal Recessive Polycystic Kidney Disease – PKHD1. 2001 Jul 19 [Updated 2024 Apr 4]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1326/ 26.Simonini, C., Fröschen, E. M., Nadal, J., Strizek, B., Berg, C., Geipel, A., & Gembruch, U. (2023). Prenatal ultrasound in fetuses with polycystic kidney appearance - expanding the diagnostic algorithm. Archives of gynecology and obstetrics, 308(4), 1287–1300. 27.Kobayashi, K., Bang Lu, Y., Xian Li, M., Nishi, I., Hsiao, K. J., Choeh, K., Yang, Y., Hwu, W. L., Reichardt, J. K., Palmieri, F., Okano, Y., & Saheki, T. (2003). Screening of nine SLC25A13 mutations: their frequency in patients with citrin deficiency and high carrier rates in Asian populations. Molecular genetics and metabolism, 80(3), 356–359. 28.Chen, S. T., Su, Y. N., Ni, Y. H., Hwu, W. L., Lee, N. C., Chien, Y. H., Chang, C. C., Chen, H. L., & Chang, M. H. (2012). Diagnosis of neonatal intrahepatic cholestasis caused by citrin deficiency using high-resolution melting analysis and a clinical scoring system. The Journal of pediatrics, 161(4), 626–31.e2. 29.Lu, Y. B., Kobayashi, K., Ushikai, M., Tabata, A., Iijima, M., Li, M. X., Lei, L., Kawabe, K., Taura, S., Yang, Y., Liu, T. T., Chiang, S. H., Hsiao, K. J., Lau, Y. L., Tsui, L. C., Lee, D. H., & Saheki, T. (2005). Frequency and distribution in East Asia of 12 mutations identified in the SLC25A13 gene of Japanese patients with citrin deficiency. Journal of human genetics, 50(7), 338–346. 30.Wang, L. Y., Chen, N. I., Chen, P. W., Chiang, S. C., Hwu, W. L., Lee, N. C., & Chien, Y. H. (2013). Newborn screening for citrin deficiency and carnitine uptake defect using second-tier molecular tests. BMC medical genetics, 14, 24. 31.Konkle BA, Nakaya Fletcher S. Hemophilia A. 2000 Sep 21 [Updated 2023 Jul 27]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1404/ 32.Downes, K., Megy, K., Duarte, D., Vries, M., Gebhart, J., Hofer, S., Shamardina, O., Deevi, S. V. V., Stephens, J., Mapeta, R., Tuna, S., Al Hasso, N., Besser, M. W., Cooper, N., Daugherty, L., Gleadall, N., Greene, D., Haimel, M., Martin, H., Papadia, S., … Freson, K. (2019). Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders. Blood, 134(23), 2082–2091. 33.Lannoy, N., Abinet, I., Bosmans, A., Lambert, C., Vermylen, C., & Hermans, C. (2012). Computational and molecular approaches for predicting unreported causal missense mutations in Belgian patients with haemophilia A. Haemophilia : the official journal of the World Federation of Hemophilia, 18(3), e331–e339. 34.Zhu, Y., Chen, Q., Lin, H., Lu, H., Qu, Y., Yan, Q., & Wang, C. (2022). FGD1 Variant Associated With Aarskog-Scott Syndrome. Frontiers in pediatrics, 10, 888923. 35.Zanetti Drumond, V., Sousa Salgado, L., Sousa Salgado, C., Oliveira, V. A. L., de Assis, E. M., Campos Ribeiro, M., Furtado Valadão, A., & Orrico, A. (2021). The Prevalence of Clinical Features in Patients with Aarskog-Scott Syndrome and Assessment of Genotype-Phenotype Correlation: A Systematic Review. Genetics research, 2021, 6652957. 36.Mehta A, Hughes DA. Fabry Disease. 2002 Aug 5 [Updated 2024 Apr 11]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1292/ 37.Hwu, W. L., Chien, Y. H., Lee, N. C., Chiang, S. C., Dobrovolny, R., Huang, A. C., Yeh, H. Y., Chao, M. C., Lin, S. J., Kitagawa, T., Desnick, R. J., & Hsu, L. W. (2009). Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). Human mutation, 30(10), 1397–1405. 38.Chien, Y. H., Lee, N. C., Chiang, S. C., Desnick, R. J., & Hwu, W. L. (2012). Fabry disease: incidence of the common later-onset α-galactosidase A IVS4+919G→A mutation in Taiwanese newborns--superiority of DNA-based to enzyme-based newborn screening for common mutations. Molecular medicine (Cambridge, Mass.), 18(1), 780–784. 39.Lin, H. Y., Chong, K. W., Hsu, J. H., Yu, H. C., Shih, C. C., Huang, C. H., Lin, S. J., Chen, C. H., Chiang, C. C., Ho, H. J., Lee, P. C., Kao, C. H., Cheng, K. H., Hsueh, C., & Niu, D. M. (2009). High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circulation. Cardiovascular genetics, 2(5), 450–456. 40.Hwu W. L. (2023). Deciphering the diagnostic dilemma: A comprehensive review of the Taiwanese cardiac variant in Fabry disease. Journal of the Formosan Medical Association = Taiwan yi zhi, S0929-6646(23)00402-3. Advance online publication. 41.Wu, C. C., Hung, C. C., Lin, S. Y., Hsieh, W. S., Tsao, P. N., Lee, C. N., Su, Y. N., & Hsu, C. J. (2011). Newborn genetic screening for hearing impairment: a preliminary study at a tertiary center. PloS one, 6(7), e22314. 42.Barbarino, J. M., McGregor, T. L., Altman, R. B., & Klein, T. E. (2016). PharmGKB summary: very important pharmacogene information for MT-RNR1. Pharmacogenetics and genomics, 26(12), 558–567. 43.Lee H. H. (2014). Mutational analysis of CYP21A2 gene and CYP21A1P pseudogene: long-range PCR on genomic DNA. Methods in molecular biology (Clifton, N.J.), 1167, 275–287. 44.Han, Y., Zhang, L., Tao, H., Wu, J., & Zhai, J. (2023). Genetic analysis and management of a familial hypercholesterolemia pedigree with polygenic variants: Case report. Medicine, 102(32), e34534. 45.Ison HE, Clarke SL, Knowles JW. Familial Hypercholesterolemia. 2014 Jan 2 [Updated 2022 Jul 7]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK174884/ 46.Huang, C. C., Niu, D. M., & Charng, M. J. (2022). Genetic Analysis in a Taiwanese Cohort of 750 Index Patients with Clinically Diagnosed Familial Hypercholesterolemia. Journal of atherosclerosis and thrombosis, 29(5), 639–653. 47.Chiou, K. R., & Charng, M. J. (2012). Common mutations of familial hypercholesterolemia patients in Taiwan: characteristics and implications of migrations from southeast China. Gene, 498(1), 100–106. 48.Chen, Y. J., Chen, I. C., Chen, Y. M., Hsiao, T. H., Wei, C. Y., Chuang, H. N., Lin, W. W., & Lin, C. H. (2022). Prevalence of genetically defined familial hypercholesterolemia and the impact on acute myocardial infarction in Taiwanese population: A hospital-based study. Frontiers in cardiovascular medicine, 9, 994662. 49.Roberts AE. Noonan Syndrome. 2001 Nov 15 [Updated 2022 Feb 17]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1124/ 50.El Bouchikhi, I., Belhassan, K., Moufid, F. Z., Iraqui Houssaini, M., Bouguenouch, L., Samri, I., Atmani, S., & Ouldim, K. (2016). Noonan syndrome-causing genes: Molecular update and an assessment of the mutation rate. International journal of pediatrics & adolescent medicine, 3(4), 133–142. 51.Baldo, F., Fachin, A., Da Re, B. et al. New insights on Noonan syndrome’s clinical phenotype: a single center retrospective study. BMC Pediatr 22, 734 (2022). 52.Han JY, Park J. Paternally Inherited Noonan Syndrome Caused by a PTPN11 Variant May Exhibit Mild Symptoms: A Case Report and Literature Review. Genes. 2024; 15(4):445. 53.Wu, C. C., Tsai, C. Y., Lin, Y. H., Chen, P. Y., Lin, P. H., Cheng, Y. F., Wu, C. M., Lin, Y. H., Lee, C. Y., Erdenechuluun, J., Liu, T. C., Chen, P. L., & Hsu, C. J. (2019). Genetic Epidemiology and Clinical Features of Hereditary Hearing Impairment in the Taiwanese Population. Genes, 10(10), 772. 54.Huang, Y., Yang, X. L., Chen, W. X., Duan, B., Lu, P., Wang, Y., & Xu, Z. M. (2015). Prevalence of p.V37I variant of GJB2 among Chinese infants with mild or moderate hearing loss. International journal of clinical and experimental medicine, 8(11), 21674–21678. 55.Lin, Y. F., Lin, H. C., Tsai, C. L., & Hsu, Y. C. (2022). GJB2 mutation spectrum in the Taiwanese population and genotype-phenotype comparisons in patients with hearing loss carrying GJB2 c.109G>A and c.235delC mutations. Hearing research, 413, 108135. 56.Chiang, S. H., Wu, S. J., Wu, K. F., & Hsiao, K. J. (1999). Neonatal screening for glucose-6-phosphate dehydrogenase deficiency in Taiwan. The Southeast Asian journal of tropical medicine and public health, 30 Suppl 2, 72–74. 57.Chien, Y. H., Lee, N. C., Wu, S. T., Liou, J. J., Chen, H. C., & Hwu, W. L. (2008). Changes in incidence and sex ratio of glucose-6-phosphate dehydrogenase deficiency by population drift in Taiwan. The Southeast Asian journal of tropical medicine and public health, 39(1), 154–161. 58.Chang, J. G., Chiou, S. S., Perng, L. I., Chen, T. C., Liu, T. C., Lee, L. S., Chen, P. H., & Tang, T. K. (1992). Molecular characterization of glucose-6-phosphate dehydrogenase (G6PD) deficiency by natural and amplification created restriction sites: five mutations account for most G6PD deficiency cases in Taiwan. Blood, 80(4), 1079–1082. 59.Wu, C. C., Chiu, Y. H., Chen, P. J., & Hsu, C. J. (2007). Prevalence and clinical features of the mitochondrial m.1555A>G mutation in Taiwanese patients with idiopathic sensorineural hearing loss and association of haplogroup F with low penetrance in three families. Ear and hearing, 28(3), 332–342. 60.Tercyak, K. P., Johnson, S. B., Roberts, S. F., & Cruz, A. C. (2001). Psychological response to prenatal genetic counseling and amniocentesis. Patient education and counseling, 43(1), 73–84. 61.Lerman, C., Croyle, R. T., Tercyak, K. P., & Hamann, H. (2002). Genetic testing: psychological aspects and implications. Journal of consulting and clinical psychology, 70(3), 784–797. 62.Kukulu, K., Buldukoglu, K., Keser, I., Keser, I., Simşek, M., Mendilcioğlu, I., & Lüleci, G. (2006). Psychological effects of amniocentesis on women and their spouses: importance of the testing period and genetic counseling. Journal of psychosomatic obstetrics and gynaecology, 27(1), 9–15. 63.Harada-Shiba, M., Arai, H., Ohmura, H., Okazaki, H., Sugiyama, D., Tada, H., Dobashi, K., Matsuki, K., Minamino, T., Yamashita, S., & Yokote, K. (2023). Guidelines for the Diagnosis and Treatment of Adult Familial Hypercholesterolemia 2022. Journal of atherosclerosis and thrombosis, 30(5), 558–586. 64.Chou, C. T., Soong, B. W., Lin, K. P., Tsai, Y. S., Jih, K. Y., Liao, Y. C., & Lee, Y. C. (2020). Clinical characteristics of Taiwanese patients with Hereditary spastic paraplegia type 5. Annals of clinical and translational neurology, 7(4), 486–496. 65.Shieh, J. J., & Lin, C. Y. (1998). Frequent mutation in Chinese patients with infantile type of GSD II in Taiwan: evidence for a founder effect. Human mutation, 11(4), 306–312. 66.Lee, Y. J., Tsai, L. P., Niu, D. M., Shu, S. G., Chao, M. C., & Lee, H. H. (2009). The gene founder effect of two spontaneous mutations in ethnic Chinese (Taiwanese) CAH patients with 21-hydroxylase deficiency. Molecular genetics and metabolism, 97(1), 75–79. 67.Chien, Y. H., Chiang, S. C., Huang, A., Chou, S. P., Tseng, S. S., Huang, Y. T., & Hwu, W. L. (2004). Mutation spectrum in Taiwanese patients with phenylalanine hydroxylase deficiency and a founder effect for the R241C mutation. Human mutation, 23(2), 206. | - |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/94954 | - |
| dc.description.abstract | 臺灣近年來面臨少子化及生育年齡高齡化之影響，對於胎兒的基因及健康重視程度提升，也促使政府重視產前檢驗的福利政策，隨著產檢醫療及檢驗技術的進步，除了傳統染色體檢驗外，更可以應用次世代定序檢驗更多疾病，透過其高通量、快速分析和高靈敏度的特性，用以預防疾病對於家庭功能、經濟系統及醫療資源造成的衝擊。
我們應用次世代定序技術進行胎兒基因分析，並根據臺灣人相對常見的疾病基因變異，設計成390個基因的檢驗組套，以其中101個基因為主要檢測組套，剩餘289個基因為次要檢測組套。回溯2021年至2023年間，共1830筆基因檢測結果，833筆無異常、 893筆異常帶因，94筆致病異常，依照基因遺傳模式、數量分組統計及討論。 統計結果顯性表現疾病25筆、隱性表現疾病為29筆、性聯表現疾病39筆及粒線體表現1筆，疾病包括聽力損傷、外觀、代謝性、器官發育、各項發展異常之疾病等，基因型別多數與國人常見之變異吻合，接著我們透過父母親的基因檢測結果，確認胎兒基因變異的形式，用以作為臨床診斷之參考。此外部分異常疾病更為產前超音波無法偵測之問題，對於臨床診斷和遺傳諮詢提供重要的資訊。 透過兩年來基因檢驗結果的整理，並分析基因型別後，我們認為此項檢測具有價值性，即使檢驗裡仍有許多需要克服的問題，但能提供家庭及早發現、預防、準備及決定，同時也對於產前醫療提供更多資訊參考。我們希望可以將此研究作為未來效益分析的基礎，並能建置完整的遺傳諮詢流程，讓產前檢驗更加完善。 | zh_TW |
| dc.description.abstract | In recent years, Taiwan has faced the impacts of a declining birth rate and an increase in the age of childbearing, leading to greater emphasis on fetal genetics and health. This has prompted the government to prioritize prenatal examination welfare policies. With advancements in prenatal medical care and testing technology, in addition to traditional chromosomal testing, next-generation sequencing (NGS) can be used to detect a wider range of diseases. The high throughput, rapid analysis, and high sensitivity of NGS help prevent diseases' impact on family functions, economic systems, and medical resources.
We applied NGS technology to analyze fetal genes, designing a panel of 390 genes based on the relatively common genetic variations in the Taiwanese population. Of these, 101 genes were used as the primary gene set, while the remaining 289 genes formed the secondary gene set. From 2021 to 2023, we analyzed a total of 1,830 genetic test results: 833 were normal, 893 carried abnormal variations, and 94 were pathogenic abnormalities. The results were categorized and discussed according to genetic inheritance patterns and quantities. Statistical results showed 25 cases of dominant diseases, 29 cases of recessive diseases, 39 cases of X-linked diseases, and 1 case of mitochondrial disease. The diseases detected included hearing loss, appearance, metabolic disorders, organ development issues, and various developmental abnormalities. The majority of genotypes matched the common variations found in the Taiwanese population. We further verified the forms of fetal genetic variations through parental genetic test results, providing important references for clinical diagnosis. Some abnormalities detected were beyond the reach of prenatal ultrasound, offering critical information for clinical diagnosis and genetic counseling. Through the compilation and analysis of genetic test results over the past two years, we believe that this testing method is valuable. Despite the many challenges that still need to be addressed, it can help families to detect, prevent, prepare, and make informed decisions early on. It also provides more information for prenatal medical care. We hope this study can serve as a foundation for future benefit analysis and the establishment of a comprehensive genetic counseling process, improving the overall prenatal examination framework. | en |
| dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2024-08-21T16:52:36Z No. of bitstreams: 0 | en |
| dc.description.provenance | Made available in DSpace on 2024-08-21T16:52:36Z (GMT). No. of bitstreams: 0 | en |
| dc.description.tableofcontents | 口試委員會審定書 I
誌謝 II 中文摘要 III ABSTRACT IV 目 次 V 圖 次 VII 表 次 VIII 第一章 研究背景與目的 1 第二章 研究方法 3 2.1 主要基因及次要基因之組套設計及判讀流程 3 2.1.1 組套設計 3 2.1.2 判讀規則及報告登載 3 2.1.3 父母基因檢測 4 2.2 研究資料蒐集及分組流程 5 2.3 其他資料蒐集 5 2.4 次世代定序技術 5 2.5 倫理審查 6 第三章 結果 7 分類一、聽力損傷 7 分類二、葡萄糖六磷酸鹽脫氫酵素缺乏症 7 分類三、其他基因 8 第四章 討論 16 第五章 參考文獻 26 附錄.1：主要基因組套之101項基因 47 附錄.2：次要基因組套之298項基因列表 48 | - |
| dc.language.iso | zh_TW | - |
| dc.title | 應用次世代定序進行胎兒基因檢測之分析 | zh_TW |
| dc.title | An Analysis of the Application of Next-Generation Sequencing for Fetal Genetic Testing | en |
| dc.type | Thesis | - |
| dc.date.schoolyear | 112-2 | - |
| dc.description.degree | 碩士 | - |
| dc.contributor.oralexamcommittee | 李建南;柯滄銘 | zh_TW |
| dc.contributor.oralexamcommittee | Chien-Nan Lee;Tsang-Ming Ko | en |
| dc.subject.keyword | 次世代定序檢測,胎兒基因檢測,產前檢驗,台灣常見疾病,帶因率, | zh_TW |
| dc.subject.keyword | Next-Generation Sequencing (NGS),Fetal Genetic Testing,Prenatal Examination,Common Diseases in Taiwan,Carrier rate, | en |
| dc.relation.page | 48 | - |
| dc.identifier.doi | 10.6342/NTU202402120 | - |
| dc.rights.note | 同意授權(限校園內公開) | - |
| dc.date.accepted | 2024-07-30 | - |
| dc.contributor.author-college | 醫學院 | - |
| dc.contributor.author-dept | 分子醫學研究所 | - |
| 顯示於系所單位： | 分子醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-112-2.pdf 授權僅限NTU校內IP使用（校園外請利用VPN校外連線服務） | 1.32 MB | Adobe PDF | 檢視/開啟 |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。